Century Therapeutics (IPSC) Competitors $0.57 +0.01 (+2.24%) Closing price 04:00 PM EasternExtended Trading$0.57 0.00 (-0.07%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC vs. VYGR, CYBN, LYEL, MEIP, LFVN, CTNM, TVGN, ACTU, GLSI, and ELDNShould you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Voyager Therapeutics (VYGR), Cybin (CYBN), Lyell Immunopharma (LYEL), MEI Pharma (MEIP), Lifevantage (LFVN), Contineum Therapeutics (CTNM), Semper Paratus Acquisition (TVGN), Actuate Therapeutics (ACTU), Greenwich LifeSciences (GLSI), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. Century Therapeutics vs. Its Competitors Voyager Therapeutics Cybin Lyell Immunopharma MEI Pharma Lifevantage Contineum Therapeutics Semper Paratus Acquisition Actuate Therapeutics Greenwich LifeSciences Eledon Pharmaceuticals Voyager Therapeutics (NASDAQ:VYGR) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Which has higher valuation and earnings, VYGR or IPSC? Voyager Therapeutics has higher revenue and earnings than Century Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$80M2.66-$65M-$1.85-2.08Century Therapeutics$6.59M7.51-$126.57M-$0.29-1.98 Do analysts rate VYGR or IPSC? Voyager Therapeutics currently has a consensus target price of $13.25, indicating a potential upside of 244.98%. Century Therapeutics has a consensus target price of $3.75, indicating a potential upside of 552.86%. Given Century Therapeutics' higher probable upside, analysts clearly believe Century Therapeutics is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Century Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in VYGR or IPSC? 48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by insiders. Comparatively, 5.0% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to VYGR or IPSC? In the previous week, Century Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for Century Therapeutics and 7 mentions for Voyager Therapeutics. Century Therapeutics' average media sentiment score of 0.24 beat Voyager Therapeutics' score of 0.05 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, VYGR or IPSC? Voyager Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Is VYGR or IPSC more profitable? Century Therapeutics has a net margin of -19.10% compared to Voyager Therapeutics' net margin of -253.49%. Century Therapeutics' return on equity of -11.69% beat Voyager Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-253.49% -37.65% -28.89% Century Therapeutics -19.10%-11.69%-6.60% SummaryCentury Therapeutics beats Voyager Therapeutics on 12 of the 17 factors compared between the two stocks. Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPSC vs. The Competition Export to ExcelMetricCentury TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.49M$2.48B$5.70B$9.79BDividend YieldN/A1.68%3.77%4.10%P/E Ratio-1.9821.5730.8625.27Price / Sales7.51547.68403.8888.61Price / CashN/A25.4525.2228.45Price / Book0.305.559.516.00Net Income-$126.57M$31.83M$3.26B$265.34M7 Day Performance17.32%4.88%4.50%2.79%1 Month Performance-1.10%4.00%5.22%1.51%1 Year Performance-64.32%11.04%31.92%25.40% Century Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPSCCentury Therapeutics3.0115 of 5 stars$0.57+2.2%$3.75+552.9%-65.1%$49.49M$6.59M-1.98170Earnings ReportAnalyst DowngradeVYGRVoyager Therapeutics3.6957 of 5 stars$3.09-1.8%$13.25+329.4%-42.3%$174.17M$80M-1.67100CYBNCybin2.4415 of 5 stars$7.26-2.6%$85.00+1,070.8%N/A$171.26MN/A-1.6650Positive NewsLYELLyell Immunopharma3.2969 of 5 stars$10.58-3.6%$15.00+41.8%-56.6%$169.72M$60K-0.42270Earnings ReportAnalyst DowngradeMEIPMEI Pharma1.952 of 5 stars$4.83-6.9%N/A+54.3%$167.99M$65.30M-1.02100Gap UpLFVNLifevantage4.1298 of 5 stars$13.76+3.5%$30.50+121.7%+68.0%$167.42M$200.16M19.94260CTNMContineum Therapeutics3.4757 of 5 stars$6.43-0.6%$22.50+249.9%-56.9%$167.39M$50M-2.9231News CoverageAnalyst ForecastShort Interest ↓TVGNSemper Paratus Acquisition3.7491 of 5 stars$0.98+8.8%$10.00+920.4%+35.5%$165.60MN/A0.003Analyst ForecastACTUActuate Therapeutics2.2567 of 5 stars$8.01-0.1%$20.50+155.9%-6.7%$164.17MN/A0.0010Earnings ReportAnalyst ForecastGLSIGreenwich LifeSciences1.374 of 5 stars$12.49+2.5%$39.00+212.2%-12.5%$162.83MN/A-9.913Earnings ReportELDNEledon Pharmaceuticals1.8719 of 5 stars$2.71-0.4%$10.00+269.0%-3.7%$162.58MN/A-1.2910Earnings ReportShort Interest ↑ Related Companies and Tools Related Companies VYGR Alternatives CYBN Alternatives LYEL Alternatives MEIP Alternatives LFVN Alternatives CTNM Alternatives TVGN Alternatives ACTU Alternatives GLSI Alternatives ELDN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPSC) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access